Browsing Tag
Susan Galbraith
5 posts
AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union (EU) for the treatment…
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with…
AstraZeneca to acquire cell therapy company Neogene Therapeutics
AstraZeneca will acquire Neogene Therapeutics, a US-based clinical-stage biotechnology company, for a total consideration of up to $320…
AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination…
DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2…